Mecasermin rinfabate - Shire

Drug Profile

Mecasermin rinfabate - Shire

Alternative Names: HGT-ROP-001; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Mecasermin rinfabate; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insmed
  • Developer Insmed; Shire
  • Class Antihyperglycaemics; Growth factors
  • Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Insulin resistance; Growth disorders; Retinopathy of prematurity; Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung disorders; Retinopathy of prematurity
  • Market Withdrawal Growth disorders
  • Suspended Muscular dystrophies
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 Phase-II clinical trials in Lung disorders (Prevention) in USA (unspecified route) (Shire pipeline, February 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-disorders(In neonates, Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top